Shionogi & Co., Ltd. 4507
TSE · Japan · Health Technology
¥2,852.00-18.50 (-0.64%)
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · JPY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Shionogi & Co Ltd (SGIOF) recently announced a total dividend of $0.24 per share, with the ex-dividend date set for 2026-09-29. This upcoming payment includes a $0.24 per share cash dividend, though the payable date is currently listed as 0000-00-00, indicating that the specific payment date has not yet been confirmed in the available data. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.
FLORHAM PARK, N.J., September 09, 2026--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will present findings from across its broad anti-infective portfolio at IDWeek 2026 (October 21-24, 2026), in Washington, D.C.
OSAKA, Japan, August 28, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option, under Project BioShield funding, from its April 2026 contract with Shionogi Inc., a New Jersey-based subsidiary of Shionogi, to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gra
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.